Smartest Doc
Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia
Cancer Chemotherapy and Pharmacology, 06/04/2012
Yin OQP et al. – Concurrent use of proton pump inhibitors (PPIs) or H2 blockers did not affect the pharmacokinetics and efficacy of nilotinib in patients with positive (Ph+) chronic myeloid leukemia in chronic phase (Ph+ CML–CP).